Search clinical trials for: LAF237 placebo

Total 53470 results

Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety LMF237 in Patients With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Vildagliptin Monotherapy (CLMF237A1303)

Diabetes Mellitus, Type 2

Japan
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)

Neuromyelitis Optica (NMO) | NMO Spectrum Disorder (NMOSD)

United States, Korea, Republic of, Malaysia, Turkey, Bulgaria, Canada, Poland, Puerto Rico, Romania, Croatia, Georgia, Italy, Philippines, Taiwan, Ukraine
Novartis Pharmaceuticals

Completed

Early add-on Vildagliptin in Patients With Type 2 Diabetes Inadequately Controlled by Metformin

Type-2 Diabetes Mellitus

Hong Kong
Novartis Pharmaceuticals

Completed

VERIFY:A Study to Compare Combination Regimen With Vildagliptin & Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Spain, Poland, South Africa, Taiwan, Hong Kong, Norway, Italy, Bulgaria, Latvia, Lithuania, Germany, Turkey, Argentina, Israel, Korea, Republic of, Dominican Republic, Guatemala, Brazil, Colombia, Peru, Philippines, Russian Federation and more
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin as add-on Therapy to Metformin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Japan
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin 50mg Bid as an add-on Therapy to Insulin With or Without Metformin, in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

China, Thailand, Philippines, Singapore
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin Compared to Placebo in Patients With Type 2 Diabetes and Mild Hyperglycemia

Diabetes Mellitus, Type 2

Switzerland, Germany
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Vildagliptin Versus NPH Insulin add-on to Glimepiride in Type 2 Diabetes Mellitus Patients. (BENEFIT)

Type 2 Diabetes Mellitus

Germany
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Vildagliptin as add-on Insulin Therapy in T2DM Patients

Type 2 Diabetes Mellitus (T2DM)

Japan
Karus Therapeutics Limited

Completed

The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110β/δ Inhibitor) In B Cell Lymphoma

Lymphoma, B Cell

United States
Novartis Pharmaceuticals

Completed

Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Germany
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)

Neuromyelitis Optica (NMO) | NMO Spectrum Disorder (NMOSD)

Spain, Italy, United States, Japan, Poland, Taiwan, Germany, United Kingdom, Hungary, France, Ukraine
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Triangle Pharmaceuticals

Completed

A Study of MKC-442 in HIV-Positive Patients

HIV Infections
Novartis

Terminated

Assessment of the Skin-concentration of Vildagliptin 50 mg Every 12 Hours for 10 Days in Healthy Subjects and Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Novartis

Completed

Safety, Tolerability, Effect of Vildagliptin and How the Body Changes the Blood Level of Vildagliptin in Healthy Chinese Volunteers

Healthy

China
Novartis Pharmaceuticals

Completed

Efficacy of VIldagliptin aS an Add-on Therapy to Metformin Compared to Metformin Up-TitratION in Chinese Patients With Type 2 Diabetes.(VISION)

Type 2 Diabetes

China
Novartis

Completed

Bioequivalence of Vildagliptin Tablet Manufactured in China Compared to Imported Vildagliptin Tablet in Chinese Healthy Volunteers

Healthy

China
Mayo Clinic
Novartis Pharmaceuticals

Completed

The Effects of LAF237 on Gastric Function in Type 2 Diabetes

Diabetes Mellitus, Non-Insulin-Dependent

United States
Novartis

Completed

Pharmacokinetic Study of Vildagliptin in Patients With Renal Impairment

Type-2 Diabetes

Germany, United States
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Vildagliptin Plus Metformin (SPC) Treatment in Type 2 Diabetes Mellitus Patients

Diabetes Mellitus, Type 2

Taiwan
Azienda Ospedaliero-Universitaria di Parma

Completed

Effect of Vildagliptin vs. Glibenclamide on Circulating Endothelial Progenitor Cell Number Type 2 Diabetes

Type 2 Diabetes

Italy
Novartis Pharmaceuticals

Completed

Vildagliptin vs Sitagliptin add-on to Insulin - Impact on Glycemic Profile and Correlation of Hypoglycemic Episodes and Heart Function (CGM-VISIT)

Diabetes Mellitus Type 2

Germany
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Germany
Ege University

Completed

Care to Caregiver: The Effect of Reflexology on Sleep and Anxiety of Cancer Caregiver

Sleep | Anxiety

Turkey
Orphan Australia

Completed

VSL#3 Versus Placebo in Maintenance of Remission in Crohn's Disease

Crohn's Disease

Australia
Washington University School of Medicine

Completed

Alirocumab and Reverse Cholesterol Transport

Atherosclerosis | Coronary Heart Disease

United States
Assistance Publique - Hôpitaux de Paris
Iltoo Pharma

Completed

Low Dose IL-2 Therapy in Patients With a Depressive Episode in the Course of a Bipolar Disorder (DEPIL-2)

Bipolar Depression

France
Nowarta Biopharma Inc

Completed

A Phase I/II Double-blind Safety and Efficacy Evaluation of Nowarta110 in Patients With Plantar Warts

Plantar Warts

United States
Chinese University of Hong Kong

Recruiting

RCT for Yinqiaosan-Maxingganshitang in the Treatment of COVID-19

COVID-19

Hong Kong
National University of Malaysia
Malaysia Palm Oil Board

Unknown

Supplementation of Oil Palm Phenolics to Healthy Participants (SPIRAL)

Cardiovascular Diseases | Hypercholesterolemia | Hyperlipidemias

Malaysia
Medtronic Cardiac Rhythm and Heart Failure
Medtronic

Completed

Continued Access Protocol (CAP-AF)

Atrial Fibrillation

United States
Novartis Pharmaceuticals

Completed

Drug Interaction of Vildagliptin (LAF237) With Voglibose in Japanese Patients With Type 2 Diabetes

Type 2 Diabetes

Japan
John Paul II Hospital, Krakow
National Center for Research and Development, Poland; KCRI

Active, not recruiting

Cardiovascular Clinical Project to Evaluate the Regenerative Capacity of CardioCell in Patients With No-option Critical Limb Ischemia (N-O CLI)

Critical Limb Ischemia

Poland
John Paul II Hospital, Krakow
National Center for Research and Development, Poland; KCRI

Completed

Randomized Clinical Trial to Evaluate the Regenerative Capacity of CardioCell in Patients With Chronic Ischaemic Heart Failure (CIHF)

Heart Failure

Poland
Gladwin, Mark, MD
National Institutes of Health (NIH); National Institute on Aging (NIA)

Completed

Nitrites, Skeletal Muscle Mitochondrial Bioenergetics, and Physical Activity in Old Age (Nitrite)

Sedentary Lifestyle | Frailty | Aging

United States
Mersin University

Completed

The Effect of Post-Cesarean Section Acupressure on the Severity of Pain and First Mobilization Distance (Acupress)

Pain | Mobilization

Turkey
University of South Carolina
U.S. Army Medical Research and Development Command

Completed

Dietary Seaweed and Early Breast Cancer: A Randomized Trial

Seaweed Associated Changes in Healthy Subjects

United States
LEO Pharma

Completed

Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).

Atopic Dermatitis

United States, Belgium, Canada, Australia, France, Germany, Japan, Netherlands, Poland, United Kingdom
Guang'anmen Hospital of China Academy of Chinese...
Hubei Hospital of Traditional Chinese Medicine; Hebei Yiling Hospital; The First... and other collaborators

Unknown

The Multi-Centric Clinical Study of Chinese Medicine Intervention on Diabetes Distal Symmetric Polyneuropathy.

Type 2 Diabetes Mellitus
John Paul II Hospital, Krakow
National Center for Research and Development, Poland; KCRI

Completed

Cardiovascular Clinical Project to Evaluate the Regenerative Capacity of CardioCell in Patients With Acute Myocardial Infarction (AMI)

Myocardial Infarction

Poland
Resverlogix Corp

Not yet recruiting

A Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With Hemodialysis

Kidney Failure, Chronic
Fengmei Lian
Guang'anmen Hospital of China Academy of Chinese Medical Sciences; Hubei Hospital... and other collaborators

Unknown

Clinical Study of Tang Wang Prescription Intervene Diabetic Non-proliferative Retinopathy

Type2 Diabetes | Diabetic Non-proliferative Retinopathy
Shengjing Hospital

Completed

Efficacy of Chinese Herbal Medicine Xiaojidaozhi Decoction in the Treatment of Childhood Constipation

Constipation | Chinese Herbal Medicine

China
AstraZeneca

Completed

A Study of AZD8233 in Participants With Dyslipidemia. (HAYATE)

Dyslipidemia

Japan
Albert Einstein College of Medicine

Completed

Sodium Bicarbonate Supplementation in Chronic Kidney Disease Evaluation of Dose Response, Safety and Beneficial Effects

Chronic Kidney Disease

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Greater Washington Community Foundation

Terminated

Muscadine Plus (MPX) In Men With Prostate Cancer

Adenocarcinoma of the Prostate

United States
Novartis Pharmaceuticals

Completed

A Study of Inclisiran in Participants With Homozygous Familial Hypercholesterolemia (HoFH) (ORION-5)

Homozygous Familial Hypercholesterolemia

Hong Kong, Israel, Russian Federation, Serbia, South Africa, Taiwan, Turkey, Ukraine
Fengmei Lian
Peking Union Medical College Hospital; Huashan Hospital; Chengdu University of... and other collaborators

Unknown

Post-marketing Evaluation of Mudan Granule Intervention on Type 2 Diabetic Peripheral Neuropathy

Diabetic Peripheral Neuropathy Type 2

China

Search clinical trials for: LAF237 placebo

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Spain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations